<DOC>
	<DOCNO>NCT01906216</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , control study aim evaluate efficacy safety sorafenib combine transarterial chemoembolization ( TACE ) advance hepatocellular carcinoma ( HCC ) patient compare sorafenib alone , determine prognostic factor influence survival . Data efficacy safety sorafenib combination TACE patient advance HCC lack . Because western country , advance HCC consider contraindication TACE treatment . However , clinical practice pattern differ markedly Asia western country : Asia TACE perform select advanced HCC patient . We consider sorafenib combine TACE could achieve good survival benefit sorafenib alone select advanced HCC patient .</brief_summary>
	<brief_title>Sorafenib Chemoembolization Evaluation Controlled Trial</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To compare overall survival select advanced HCC patient treat sorafenib combined TACE sorafenib alone . SECONDARY OBJECTIVES : 1 . To compare time progression ( TTP ) . 2 . To compare tumor response disease control rate accord Response Evaluation Criteria Solid Tumors ( RECIST ) , modify Response Evaluation Criteria Solid Tumors ( mRECIST ) European Association Liver Disease ( EASL ) criterion . 3 . To compare safety . OTHER OBJECTIVES : 1 . To explore prognostic value AFP response treatment . OUTLINE : This multicenter , phase 3 , prospective , randomize , control trial . Patients stratify accord 1 . ECOG ( 0 vs. 1 ) 2 . Child-Pugh ( A vs. B7 ) 3 . Tumor burden 1. single vs. multiple lesion 2. tumor size ( &gt; 8cm vs. ≤8cm ) 3. vascular invasion ( yes vs. ) 4. extrahepatic metastasis ( yes vs. ) 4 . Alpha fetoprotein ( AFP ) ( ≤ 200 ng/mL vs. &gt; 200 ng/mL ) Patients randomize 1 2 treatment arm . ARM I : Patients receive two tablet sorafenib ( 200 mg tablet ) twice daily ( morning evening ) . Patients undergo first conventional transarterial chemoembolization ( TACE ) within 3-7 day first administration sorafenib . The conventional TACE consist injection contain mixture chemotherapeutic agent ( doxorubicin ) lipiodol follow embolization polyvinyl alcohol ( PVA ) complete stasis achieve tumor-feeding vessel . Tumor-feeding vessel selected/superselected whenever possible . TACE repeat `` demand '' depend radiological response . ARM II : Patients receive two tablet sorafenib ( 200 mg tablet ) twice daily ( morning evening ) . MAINTENANCE THERAPY : Standard follow-up evaluation include contrast-enhanced CT scan laboratory assessment . Laboratory assessment perform every 4 week . Radiological follow-up ( contrast-enhanced CT scan liver chest X-ray ) perform week 4 week 8 initiation treatment thereafter every 8 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Prior inform consent 2 . Advanced stage HCC/ Barcelona Clinic Liver Cancer ( BCLC ) C stage 3 . Confirmed Diagnosis HCC : 1 . Cirrhotic subject : Clinical diagnosis Asian Pacific Association Study Liver ( AASLD ) criterion . 2 . Noncirrhotic subject : subject without cirrhosis , histological cytological confirmation mandatory 3 . Documentation original biopsy diagnosis acceptable 4 . Child Pugh class A without ascites hepatic encephalopathy 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 6 . At least one unidimensional lesion measurable CTscan MRI accord RECIST , mRECIST EASL criterion , respectively 1. single lesion &gt; 5cm 2 . 23 lesion , least one lesion &gt; 3cm 4 lesion , limitation tumor size , sum size tumor lesion less 50 % liver parenchyma . 7 . Male female subject ≥ 18 year age 8 . Ability swallow oral medication 9 . Life expectancy least 12 week 10 . Both men woman enrol trial must use adequate barrier birth control measure course trial 4 week completion trial 11 . Adequate bone marrow , liver renal function assess central lab mean follow laboratory requirement sample within 7 day prior randomization : 1 . Hemoglobin &gt; 9.0 g/dl 2 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 3 . Platelet count≥50x109/L 4 . ALB≥28g/L 5 . Total bilirubin &lt; 2 mg/dL 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal 7 . Blood urea nitrogen ( BUN ) creatinine &lt; 1.5 x upper limit normal 8. International normalize ratio ( INR ) &lt; 1.7 , prothrombin time（PT） &lt; 4 second control 1 . Diffuse HCC tumor burden ≥50 % liver parenchyma 2 . Main portal vein obstruction , vascular invasion hepatic vein inferior vena cava 3 . Presence metastasis biliary tract , brain bone 4 . Poor blood supply liver tumor lesion ; poor blood supply refers tumor lesion fail show obvious contrast uptake arterial phase washout venous late phase CT scan MRI 5 . Any contraindication hepatic embolization procedure : 1 . Known hepatofugal blood flow 2 . Known portosystemic shunt 3 . Renal failure / insufficiency require hemoor peritoneal dialysis 6 . Target lesion previously treat local therapy resection HCC , radiofrequency ablation ( RFA ) , percutaneous ethanol injection ( PEI ) 7 . Other molecular target drug ongoing complete &lt; 4 week prior baseline scan 8 . Prior transarterial embolization systemic chemotherapy 9 . Any ≥ CTC adverse event ( AEs ) grade 2 acute toxic effect prior local treatment 10 . Patients untreated varix active bleed 11 . History cardiac disease : 1 . Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 2 . Uncontrolled hypertension 12 . Known history HIV infection 13 . Active clinically serious infection ( &gt; grade 2 NCICTCAE Version 3.0 ) , except Hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection 14 . Clinically significant gastrointestinal bleeding within 4 week prior start study drug 15 . Thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month prior first dose study drug 16 . Previous concurrent cancer distinct primary site histology HCC . Any cancer curatively treat &gt; 3 year prior entry permit 17 . Any contraindication sorafenib doxorubicin administration 18 . Pregnant breastfeeding subject 19 . Any disease ( within 6 month randomization ) could affect evaluation study drug 20 . Any condition unstable could jeopardize safety subject compliance study 21 . Major surgery within 4 week prior start study drug ( e.g . thoracolaparotomy allow , noninvasive surgery , e.g . biopsy , allow ) 22 . Autologous bone marrow transplant stem cell rescue within 1 year prior start study drug 23 . History organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>transarterial chemoembolization</keyword>
</DOC>